Summary & Overview
HCPCS Q5142: Adalimumab-ryvk injection, 1 mg
HCPCS Level II code Q5142 denotes a 1 mg unit of adalimumab-ryvk, a biosimilar formulation of the anti-TNF biologic adalimumab administered by injection. This code matters nationally as biosimilar adoption affects drug spending, contracting, and access to biologic therapies across outpatient and ambulatory settings. Use of a biosimilar can influence payer coverage policies, step therapy pathways, and site-of-care cost considerations.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how the code is used in billing for injectable biologic therapy, common settings of service, and which payers are relevant for reimbursement and policy reviews. The publication outlines expected benchmarks and policy-relevant information, including common modifiers and billing practices (where available), as well as clinical context for adalimumab-ryvk as a biosimilar option.
This summary provides national-level context for revenue cycle, clinical, and pharmacy leaders seeking to align coding practice with payer requirements and to monitor biosimilar utilization and coverage trends. Data not available in the input is noted where specific payer policies, taxonomies, ICD-10 mappings, and related codes would normally be detailed.
Billing Code Overview
HCPCS Level II code Q5142 indicates injection, adalimumab-ryvk biosimilar, 1 mg. This code represents a billed unit of a biosimilar form of adalimumab used for subcutaneous injection or other appropriate parenteral administration depending on clinical orders. The service type is medication administration for a biologic anti-TNF agent delivered as an injectable pharmaceutical product. The typical site of service includes outpatient infusion or injection centers, physician offices, clinics, and other ambulatory care settings where biologic injections are administered.
Clinical & Coding Specifications
Clinical Context
A 52-year-old patient with moderate-to-severe rheumatoid arthritis receives a clinic-administered subcutaneous biologic: the adalimumab-ryvk biosimilar (dose billed per Q5142 as 1 mg units). The typical workflow begins with patient check-in and verification of insurance (for example, Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, Medicare). A nurse or medical assistant confirms current medications, screens for active infections, documents weight and vital signs, and reviews prior authorization or benefit coverage. The clinician documents the indication, consent, and planned dose. The medication is prepared in the clinic or provided by the patient (depending on payer rules) and administered subcutaneously by a licensed nurse. Post-injection monitoring for allergic reaction or immediate adverse events is performed for a brief observation period. The visit note includes diagnosis, product name, lot number, injection site, and patient response. Billing uses Q5142 units to reflect the number of milligrams administered; appropriate modifiers are appended when clinically indicated (for example, modifier JW is not listed here and should not be used). Documentation supports medical necessity, quantity, and payer-specific requirements for coverage and reimbursement.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|